# A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

> **NCT01037907** · PHASE2 · TERMINATED · sponsor: **Boston Scientific Corporation** · enrollment: 173 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Pleneva TM BGC20-0134
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01037907
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 173 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2022-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01037907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01037907, "A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01037907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*